We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04690595
Recruitment Status : Recruiting
First Posted : December 30, 2020
Last Update Posted : February 13, 2023
City of Hope Medical Center
Information provided by (Responsible Party):
PeproMene Bio, Inc.

Brief Summary:
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Condition or disease Intervention/treatment Phase
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Biological: BAFFR-CAR T cells Phase 1

Detailed Description:
This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection fighting blood cells that can kill cancer cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize BAFFR, a protein on the surface of cancer cells. These BAFFR-specific T cells may help the body's immune system identify and kill BAFFR+ cancer cells.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Actual Study Start Date : May 18, 2021
Estimated Primary Completion Date : November 18, 2025
Estimated Study Completion Date : November 18, 2026

Arm Intervention/treatment
Experimental: BAFFR-CAR T cells
B-cell activating factor receptor-Chimeric antigen receptor T cells
Biological: BAFFR-CAR T cells
First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL

Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Up to 1 year post treatment ]
    Toxicity will be graded per Common Terminology Criteria for Adverse Events version 5.0, Cytokine Release Syndrome (CRS) and neurotoxicity which use the American Society for Transplantation and Cellular Therapy Consensus Criteria (ASTCT) and Graft versus Host Disease (GVHD) criteria. Toxicities will be followed from the start of lymphodepletion until the end of the study.

Secondary Outcome Measures :
  1. Disease response [ Time Frame: Up to 1 year post treatment ]
    Defined as complete response [CR], or complete response with incomplete blood count recovery [CRi], or complete response with partial hematological recovery [CRh]. Response will be evaluated using European Leukemia Net (ELN) criteria. Rates and associated 95% binomial exact confidence limits will be estimated (CR/CRi/CRh) rate.

  2. Minimal residual disease (MRD) [ Time Frame: Up to 1 year post treatment ]
    Negative MRD is defined by malignant cells < 0.01% by flow cytometry or clonoSEQ.

  3. B cell frequency [ Time Frame: Up to 1 year post treatment ]
    Measured by serum IgG level

  4. Severity of graft-versus-host disease (GVHD) in recipients of prior allogeneic hematopoietic stem cell transplantation [ Time Frame: Up to 1 year post treatment. ]
    Defined per Keystone criteria for acute GVHD and revised National Institute of Health (NIH) consensus on grading of chronic GVHD.

  5. Progression-free survival (PFS) [ Time Frame: From T cell infusion to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 15 years. ]
    Kaplan-Meier product limit method with log-log transformation for the confidence interval will be used to estimate PFS.

  6. Overall survival (OS) [ Time Frame: From the day of BAFFR-CAR T cell infusion to death from any cause assessed, up to 15 years. ]
    Kaplan-Meier product limit method with log-log transformation for the confidence interval will be used to estimate OS.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented informed consent of the participant and/or legally authorized representative.
  2. Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study PI approval.
  3. Age ≥ 18 years.
  4. ECOG ≤ 2.
  5. Life expectancy ≥ 16 weeks.
  6. Histologically confirmed B-ALL or B-cell lymphoblastic lymphoma
  7. Relapsed/refractory disease after failure of ≥ 2 prior lines of therapy.
  8. Evidence of active BAFF-R expression at the time of enrollment.
  9. Recovered to ≤ Grade 1 from the acute toxic effects (except alopecia) of prior anti-cancer therapy.
  10. No known contraindications to leukapheresis, steroids or tocilizumab.
  11. Ineligible for or failed prior CD19-targeted immunotherapy (e.g., blinatumomab or CD19-CAR T cells).

    For participants who had prior CD19-CAR T cell therapy:

    - At least 90-days has elapsed since participant received last CD19-CAR T cell therapy.


    - Persistence of prior CD19-CAR T cells must be evaluated and found to be <5% prior to leukapheresis procedure

  12. Participants with CNS involvement by leukemia (CNS2 and asymptomatic CNS3) may be considered eligible after discussions with the study team.
  13. Total serum bilirubin ≤2.0 mg/dL (unless has Gilbert's disease or leukemia involvement of the liver, then ≤3.0)
  14. AST ≤2.5 x ULN
  15. ALT ≤ 2.5 x ULN
  16. Creatinine clearance of ≥ 50 mL/min per 24-hour urine test or the Cockcroft-Gault formula
  17. Left ventricular ejection fraction (LVEF) ≥ 50%
  18. O2 saturation ≥ 92% on room air.
  19. Seronegative for HIV Ag/Ab combo, HCV*, and active HBV (Surface Antigen Negative)

    *If positive, Hepatitis C RNA quantitation must be performed and must be undetectable.

  20. Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  21. Agreement by females and males of childbearing potential^ to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy.

    ^Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

  22. A complete liver evaluation (which includes ultrasound elastography, MRI of the liver and a hepatology consult) may be done if needed based on PI's recommendation.
  23. Evaluation of acquired hemochromatosis (indicated through MRI of the liver and elevated levels of Ferritin) is recommended for participants who have undergone multiple transfusions and prior alloHCT.

Exclusion Criteria:

  1. Autologous/allogeneic stem cell transplant within 100 days at the time of enrollment.
  2. Immunosuppressant medications within 3 months prior to protocol enrollment.
  3. Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone ≤ 7.5 mg /day or equivalent) is allowed
  4. Auto-immune disease or active GVHD requiring systemic immunosuppressant therapy.
  5. Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification.
  6. Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within 2 weeks of enrollment.
  7. Any abnormal liver enzyme levels (as defined ≥ULN in ALT, AST, Bilirubin and Alkaline Phosphatase levels) at time of enrollment
  8. . Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder.
  9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
  10. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.
  11. History of venous occlusive disease (VOD), or GvHD.

    a. Subjects with a history of the following GvHD may still be included in the study: i. Resolved Grade 2 or less steroid-sensitive acute skin GvHD ii. Grade 1 gastro-intestinal (GI)-GvHD developed within 100 days post prior alloHCT.

  12. History of stroke or intracranial hemorrhage within 6 months of enrollment.
  13. History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for ≥ 3 years.
  14. Clinically significant uncontrolled illness.
  15. Active systemic uncontrolled infection requiring antibiotics.
  16. Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.
  17. Females only: Pregnant or breastfeeding.
  18. Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
  19. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04690595

Layout table for location contacts
Contact: Ting-Ying (Hazel) Cheng, PhD 714-599-8077 hazel.cheng@pepromenebio.com
Contact: Katrin Tiemann, PhD 626-359-8111 ktiemann@coh.org

Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Ibrahim Aldoss, MD    626-218-2405    ialdoss@coh.org   
Contact: Katrin Tiemann, PhD    (626) 359-8111    ktiemann@coh.org   
Sponsors and Collaborators
PeproMene Bio, Inc.
City of Hope Medical Center
Layout table for investigator information
Principal Investigator: Ibrahim Aldoss, MD City of Hope Medical Center
Layout table for additonal information
Responsible Party: PeproMene Bio, Inc.
ClinicalTrials.gov Identifier: NCT04690595    
Other Study ID Numbers: PMB-101
First Posted: December 30, 2020    Key Record Dates
Last Update Posted: February 13, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PeproMene Bio, Inc.:
B cell
relapsed or refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases